Integrating Molecular Profiles into Clinical Practice

Molecular classification has revolutionized how oncologists approach uterine malignancies. Recently, the 2023 FIGO staging criteria officially incorporated these profiles to enhance diagnostic precision. Among these, POLE-mutated endometrial cancer stands out as a unique subtype. Despite exhibiting aggressive histopathologic features, these tumors typically follow a favorable clinical course. A recent institutional study analyzed 198 cases to evaluate the impact of universal molecular testing. These findings emphasize the necessity of genomic data in modern gynecology.

Identifying POLE-mutated Endometrial Cancer in Routine Staging

The institutional data revealed that nearly 5.6% of patients harbored POLE exonuclease domain mutations. Notably, approximately half of these cases displayed aggressive features like lymphovascular invasion or high FIGO grades. However, molecular sequencing provided clarity where traditional microscopy could fail. For example, four cases initially appeared to be p53 abnormal or MMR-deficient based on immunohistochemistry alone. Universal testing correctly identified them as the ultramutated subtype. Consequently, these patients avoided potentially inappropriate risk stratification. Moreover, accurate identification ensures that patients receive the most appropriate prognostic counseling.

Furthermore, researchers found subclonal TP53 variants in nearly half of the specimens. This finding highlights the complexity of tumor heterogeneity in uterine cancers. Nevertheless, clinical outcomes remained consistently positive across both aggressive and non-aggressive morphologic groups. Therefore, clinicians must prioritize sequencing to ensure accurate staging and personalized management. This approach ultimately prevents over-treatment while providing realistic expectations for patients. In contrast to traditional methods, molecular testing offers a more nuanced view of the disease.

Frequently Asked Questions

What is the prognostic significance of the POLE mutation?

It signifies an ultramutated phenotype with an exceptionally favorable prognosis. These patients often have better outcomes even if the tumor appears aggressive under a microscope.

Can immunohistochemistry (IHC) replace POLE sequencing?

No, IHC alone cannot identify the specific POLE mutation. Sequencing is essential to prevent misclassification as other molecular subtypes like p53 abnormal or MMRd.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Warren L et al. Universal Molecular Testing for Endometrial Cancers: Institutional Experience and Focus on Phenotypic and Clinical Characterization of POLE-mutated Cases. Int J Gynecol Pathol. 2026 May 08. doi: 10.1097/PGP.0000000000001181. PMID: 42101893.

Berek JS et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162(2):383-394.

Murali R et al. Molecular classification of endometrial carcinoma and its clinical implications. J Pathol. 2023;260(5):541-555.